AstraZeneca working on a new vaccine for Omicron:3 stocks to eye on

December 22, 2021 10:17 AM CET | By Sreenivas D Ajankar
 AstraZeneca working on a new vaccine for Omicron:3 stocks to eye on
Image source: Shutterstock.com

Highlights 

  • FTSE 100 listed global pharmaceutical company AstraZeneca Pls said that it is working on developing a new vaccine for the Omicron variant.
  • Many vaccine makers like Pfizer and Moderna are working on new vaccines and hope to start the clinical trial soon.

FTSE 100 listed global pharmaceutical company AstraZeneca Plc (LON: AZN) said that it is working on developing a new vaccine for the Omicron variant. The company will work alongside Oxford University to develop the new variant-specific vaccine.  

Many vaccine makers like Pfizer and Moderna have previously announced that they are doing research work on their respective new vaccine that targets the new variants, Omicron. Also, Moderna expects to start the clinical trial of its new vaccine in January 2022; upon successful completion of clinical trials, the company will apply for vaccine approval from the health authority.

The pharmaceutical stocks witnessed a lot of buying interest from investors in the passing year. Many investors preferred investing in the pharma sector amid the vaccine development news by different companies. Many of these stocks have also given a good return to investors.

Let us explore 3 FTSE listed pharmaceutical stocks that are in focus today:

Tissue Regenix Group Plc (LON:TRX)

The company provides the technology platform for tissue engineering and regenerative medicine. It has operations in the US and other countries. In the first half of 2021, the product shipment to the US market increased by 44% resulting in group revenue of £6.8 million, a rise of 12%. The gross profit stood at £3.1 million during the period. Also, the company restructured its US commercial operation, which led to savings of USD 350,000 in the first half of 2021.

Tissue Regenix Group Plc’s stock was up by 21.3% and finally closed at GBX 0.54 on 21 December 2021, with a market cap of £31.30 million.

Poolbeg Pharma Plc (LON:POLB)

FTSE AIM-listed company is engaged in the development of products to treat infectious diseases, which is one of the fastest-growing segments within the pharma industry. The market size for the infectious diseases segment is expected to surpass USD 250 billion by 2025. The company has agreed to partner with AnaBio Technologies to develop an oral vaccine to treat contagious diseases. The company has signed a binding term sheet with AnaBio Technologies, while the full license and collaboration agreement will be signed soon.

Poolbeg Pharma Plc’s last close was at GBX 9.25 on 21 December 2021, with a market cap of £46.25 million.

Dechra Pharmaceuticals Plc (LON: DPH)

The company is one of the major veterinary pharmaceutical companies listed on the LSE. It does the research and development of high-quality veterinary products.

For the financial year ended 30 June 2021, the company reported a 21% rise in revenue at £608 million driven by strong organic growth as most of its product category outperformed. The underlying operating profit stood at £162.2 million.

The company’s business continued the strong performance in the first quarter of the new financial year, reporting solid performance in the US market mainly due to growth in the companion animal market.

Dechra Pharmaceuticals Plc’s last close was at GBX 4,968 on 21 December 2021, with a market cap of £5,382.6 million.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Sponsored Articles